FDA Set to Evaluate Benicar Link to Adverse Side Effects

The popular hypertension drug Benicar has recently been linked to an increased risk of heart attack, stroke and sudden death. The U.S. Food and Drug Administration is currently reviewing data from two clinical trials in which patients taking Benicar had a higher rate of cardiovascular-related death than those taking a placebo.

Benicar falls under a category of drugs called angiotensin-receptor blockers (ARBs) and is frequently prescribed to patients who suffer from high blood pressure.

Benicar Side Effects

During the clinical trials, originally conducted to determine whether Benicar could slow the progression of kidney disease, surprising results showed an increased risk of heart failure, stroke and sudden death among type 2 diabetes patients who were taking Benicar when compared to patients taking a placebo.

Meanwhile, the FDA is asking patients not to discontinue the use of Benicar until further notice, stating that it believes the benefits of the drug outweigh its risks. However, the agency is urging both medical practitioners and individuals using Benicar to immediately report any adverse side effects.

Benicar Lawsuits

Benicar is manufactured by Daiichi Sankyo. The pharmaceutical company, which has not yet responded to the latest data involving its product, could be facing a slew of personal injury and defective drug lawsuits if the FDA rules the findings viable.

If you or a loved one has suffered heart failure, stroke or sudden death while on Benicar, you may be eligible to receive compensation for your injuries, pain and suffering. The Pensacola personal injury attorneys of Aylstock, Witkin Kreis & Overholtz handle national litigation across the United States for victims injured by defective pharmaceuticals and medical devices. They have successfully represented and obtained substantial compensation for a number of patients who have been harmed by defective drugs. To learn more, please contact AWKO law today at (888) 255-2956.

More Benicar News From Our Blog